BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/20/2020 4:04:17 AM | Browse: 945 | Download: 2244
 |
Received |
|
2020-05-29 01:08 |
 |
Peer-Review Started |
|
2020-05-29 01:08 |
 |
First Decision by Editorial Office Director |
|
2020-06-12 18:28 |
 |
Return for Revision |
|
2020-06-12 18:28 |
 |
Revised |
|
2020-06-24 16:13 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2020-08-26 10:02 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2020-08-27 00:38 |
 |
Articles in Press |
|
2020-08-27 00:38 |
 |
Edit the Manuscript by Language Editor |
|
2020-10-16 02:13 |
 |
Typeset the Manuscript |
|
2020-11-19 01:08 |
 |
Publish the Manuscript Online |
|
2020-11-20 04:04 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Biochemistry & Molecular Biology |
| Manuscript Type |
Basic Study |
| Article Title |
Tissue microarray-chip featuring computerized immunophenotypical characterization more accurately subtypes ampullary adenocarcinoma than routine histology
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Matteo Palmeri, Niccola Funel, Gregorio Di Franco, Niccolò Furbetta, Desirée Gianardi, Simone Guadagni, Matteo Bianchini, Luca E Pollina, Claudio Ricci, Marco Del Chiaro, Giulio Di Candio and Luca Morelli |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| ARPA Foundation (www.fondazionearpa.it) |
|
|
| Corresponding Author |
Niccola Funel, BSc, PhD, Academic Research, Postdoc, Research Scientist, Division of Surgical Pathology, University-Hospital of Pisa, Via Paradisa 2, Pisa 56124, Italy. niccola.funel@gmail.com |
| Key Words |
Ampullary adenocarcinoma; Histo-molecular phenotype; Prognostic; CK7; CK20; CDX2 |
| Core Tip |
Ampullary adenocarcinomas are heterogeneous tumors with different responses to specific chemotherapy regimens and prognosis, probably because they are a heterogenous group including differing ampullary growth and overlapping of histological phenotypes. Conventional histology does not allow a definitive identification of the three subgroups. We used an immunohistochemical score based on CDX2, CK7 and CK20 and identified only two sub-types, representing two groups of apparently separate neoplastic disorders with different oncological outcomes. |
| Publish Date |
2020-11-20 04:04 |
| Citation |
Palmeri M, Funel N, Di Franco G, Furbetta N, Gianardi D, Guadagni S, Bianchini M, Pollina LE, Ricci C, Del Chiaro M, Di Candio G, Morelli L. Tissue microarray-chip featuring computerized immunophenotypical characterization more accurately subtypes ampullary adenocarcinoma than routine histology. World J Gastroenterol 2020; 26(43): 6822-6836 |
| URL |
https://www.wjgnet.com/1007-9327/full/v26/i43/6822.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v26.i43.6822 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.